US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer... (CC trials (T--FAC and FEC--docetaxel). T...)

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium

Date:12/17/2007

CC trials (T-->FAC and FEC-->docetaxel). The pCR predictive algorithm was similar, though not identical, to the T-->FAC and will be presented separately.

The study concluded that : 1) FEC100 (FEC75H)-->wXT(H) is a safe, effective preoperative chemotherapy regimen; 2) pCR was dependent on genomic subtype; 3) Microarray studies are possible in the community; and, 4) A unique microarray signature associated with pCR to FEC100-->wTX was NOT discovered but gene set enrichment analysis (GSEA) is ongoing to identify biological pathways and functionally related genes that are associated with pCR.

In addition, Joyce O'Shaughnessy, M.D., Texas Oncology, PA, Baylor-Sammons Cancer Center in Dallas, associate director for clinical research and co-chair of breast cancer research for US Oncology, delivered the following presentation at the conference:

Preliminary results of a randomized Phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer

Joyce O'Shaughnessy, Weckstein DJ, Vukelja SJ, McIntyre K, Krekow L, Holmes FA, Asmar L, Blum JL, US Oncology Research, Inc., Houston, TX; Baylor-Charles A. Sammons Cancer Center, Dallas, TX; Texas Oncology, P.A. -- Dallas Presbyterian, Dallas, TX; New Hampshire Oncology-Hematology, Hookset, NH; Tyler Cancer Center, Tyler, TX; The Breast Care Center of North Texas, Bedford, TX; Texas Oncology, P.A., Houston, TX.

About US Oncology Research

The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 500 physicians actively enrolling patients, 77 research sites, and is currently involved in more than 60 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clin
'/>"/>

13

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate

Post Your Comments:

US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer...(CC trials (T--FAC and FEC--docetaxel). T...),Health